Pancreatic Cancer Research

ResearcherChristian-Albrechts-Universität zu KielActive in the last 2 years

Holger Kalthoff

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 6 November 2026

Matched on OpenAlex author ID A5040005604. Sources: OpenAlex.

Their work

Papers
29 (first author 4, last author 8)
Trials
0
Grants
0
Labs led
2
Collaborators
78
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: 2 papers · 2014: 4 papers · 2015: 3 papers · 2016: 1 paper · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: 1 paper · 2021: 4 papers · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 29

  1. Regulation of epithelial-mesenchymal plasticity in pancreatic ductal adenocarcinoma: Role of key molecules in tumor differentiation and therapy. Co-author DOI 10.1016/j.ejca.2025.115561↗
  2. How open is the therapeutic horizon for pancreatic cancer patients? Co-author DOI 10.1016/j.hbpd.2021.11.005↗
  3. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancr… Co-author DOI 10.1053/j.gastro.2022.07.047↗
  4. Transportome Malfunctions and the Hallmarks of Pancreatic Cancer. First author DOI 10.1007/112_2020_20↗
  5. Prognostic significance of high mobility group A2 (HMGA2) in pancreatic ductal adenocarcinoma: malignant functions of cytoplasmic HMGA2 expression. Co-author DOI 10.1007/s00432-021-03745-w↗
  6. Topology impacts TRAIL therapy: Differences in primary cancer growth and liver metastasis between orthotopic and subcutaneous xenotransplants of pancreatic duc… Last author DOI 10.1016/j.hbpd.2021.04.005↗
  7. Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer. Co-author DOI 10.2967/jnumed.120.256776↗
  8. The A818-6 system as an in-vitro model for studying the role of the transportome in pancreatic cancer. Co-author DOI 10.1186/s12885-020-06773-w↗
  9. The expression of death receptor systems TRAIL-R1/-R2/-R4, CD95 and TNF-R1 and their cognate ligands in pancreatic ductal adenocarcinoma. Last author DOI 10.14670/hh-18-054↗
  10. The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells. Co-author DOI 10.1038/s41419-018-0478-0↗
  11. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. First author DOI 10.1136/gutjnl-2016-312432↗
  12. Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC. Co-author DOI 10.1186/s12885-018-4688-8↗
  13. Tumor-reducing effect of the clinically used drug clofazimine in a SCID mouse model of pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.11299↗
  14. The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.14768↗
  15. In silico analysis of the transportome in human pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00249-016-1171-9↗
  16. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Co-author DOI 10.1002/ijc.29324↗
  17. Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer. Last author DOI 10.1002/ijc.29445↗
  18. Molecular Mechanisms by Which a Fucus vesiculosus Extract Mediates Cell Cycle Inhibition and Cell Death in Pancreatic Cancer Cells. Last author DOI 10.3390/md13074470↗
  19. Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.28327↗
  20. Interleukin-6: a villain in the drama of pancreatic cancer development and progression. Last author DOI 10.1016/s1499-3872(14)60259-9↗
  21. Metabolic biomarkers for the differential diagnosis of pancreatic ductal adenocarcinoma vs. chronic pancreatitis First author DOI 10.1186/2049-3002-2-s1-p60↗
  22. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0094357↗
  23. TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1016/s1499-3872(13)60012-0↗
  24. Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/his.12115↗
  25. Lack of CCR7 expression is rate limiting for lymphatic spread of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.26502↗
  26. Characterisation of FAP-1 expression and CD95 mediated apoptosis in the A818-6 pancreatic adenocarcinoma differentiation system. Co-author DOI 10.1016/j.diff.2011.11.013↗
  27. The 'N-factors' in pancreatic cancer: functional relevance of NF-κB, NFAT and Nrf2 in pancreatic cancer. Last author DOI 10.1038/oncsis.2012.35↗
  28. Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ejcb.2010.10.008↗
  29. Emerging therapeutic targets and agents for pancreatic cancer therapy--where are we and where we have to go? First author DOI 10.2174/187152011795677418↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anna Trauzold · 11 shared papers, 2011–2021 · strength 0.95
  2. Christian Röder · 8 shared papers, 2011–2021 · strength 0.68
  3. Qi Ling · 3 shared papers, 2017–2025 · strength 0.61
  4. Christoph Röcken · 6 shared papers, 2014–2021 · strength 0.46
  5. Hendrik Ungefroren · 2 shared papers, 2012–2025 · strength 0.30
  6. Christian P. Pilarsky · 4 shared papers, 2014–2022 · strength 0.27
  7. Hendrik Lehnert · 1 shared paper, 2025 · strength 0.27
  8. Rüdiger Braun · 1 shared paper, 2025 · strength 0.27
  9. Jens Uwe Marquardt · 1 shared paper, 2025 · strength 0.27
  10. Frank Ulrich Weiß · 3 shared papers, 2014–2022 · strength 0.21
  11. Robert Grützmann · 3 shared papers, 2014–2022 · strength 0.21
  12. Julia V. Mayerle · 3 shared papers, 2014–2022 · strength 0.21
  13. Jan-Paul Gundlach · 2 shared papers, 2018–2021 · strength 0.20
  14. Doaa Tawfik · 2 shared papers, 2016–2020 · strength 0.18
  15. Angela Zaccagnino · 2 shared papers, 2017–2020 · strength 0.18
  16. Markus M. Lerch · 2 shared papers, 2018–2022 · strength 0.17
  17. Ujjwal Mukund Mahajan · 2 shared papers, 2018–2022 · strength 0.17
  18. Marius Distler · 2 shared papers, 2018–2022 · strength 0.17
  19. Bence Sipos · 3 shared papers, 2012–2021 · strength 0.17
  20. Bastian Kettler · 1 shared paper, 2021 · strength 0.17
  21. Karen Legler · 3 shared papers, 2015–2018 · strength 0.17
  22. Susanne Sebens · 3 shared papers, 2011–2016 · strength 0.15
  23. H. Schäfer · 3 shared papers, 2012–2014 · strength 0.12
  24. Albrecht Schwab · 1 shared paper, 2020 · strength 0.12
  25. Friederike Gaertner · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.